TY  - CHAP
M1  - Book, Section
TI  - Osteoclast-Targeted Therapy: Bisphosphonates and Denosumab
A1  - Smith, Matthew R.
A2  - Chabner, Bruce A.
A2  - Longo, Dan L.
PY  - 2016
T2  - Harrison's Manual of Oncology, 2e
AB  - Bone  metastases  are  a  major  cause  of  morbidity  in  patients  with  a  variety  of  malignancies  including  multiple  myeloma,  breast  cancer,  and  prostate  cancer  (1).  Bone  metastases  are  often  described  as  osteoblastic  or  osteolytic  based  on  their  radiographic  appearance.  Osteoblastic  and  osteolytic  bone  disease  represent  two  extremes  of  a  spectrum,  however,  and  osteoclast  number  and  activity  are  increased  in  most  bone  metastases,  including  typical  osteoblastic  metastases  from  prostate  cancer.  Pathological  activation  of  osteoclasts  appears  to  play  a  central  role  in  disease-related  skeletal  complications.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - hemonc.mhmedical.com/content.aspx?aid=1127647081
ER  -